GENB vs RXRX
GENB: Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein therapeutics. RXRX: Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug discovery and development process.
Side-by-side fundamentals
| Metric | GENB | RXRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.90 | $2.98 | |
| Market cap as of 2026-07-23 | $1.8B | $1.6B | |
| Net margin as of 2026-07-23 | -637.0% | -842.9% | GENB higher |
| Gross margin as of 2026-07-23 | n/a | +7.2% | |
| Operating margin as of 2026-07-23 | -737.0% | -881.3% | GENB higher |
| ROE as of 2026-07-23 | -103.7% | -54.3% | RXRX higher |
| ROA as of 2026-07-23 | -61.5% | -40.6% | RXRX higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.02 | GENB lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +11.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +23.3% | |
| Beta as of 2026-07-23 | 0.52 | 1.08 | |
| 1-year return as of 2026-07-22 close | +13.8% | -54.4% | GENB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.